Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
- Dublin, Ireland and Boston, Massachusetts-based biopharmaceutical firm focused on rare diseases - Shares delisted fr ...
FTSE Russell 06 January 2022 Amryt Pharma (UK): Constituent Deletion Changes in FTSE UK Index Series 06 January 2022 Subject to the expected cancellation of trading on AIM for Amryt Pharma (UK...
T Amryt Pharma plc - Key Dates for AIM Delisting DUBLIN, Ireland, and Boston MA, January 6, 2022, Amryt Pharma plc (Nasdaq: AMYT, AIM: AMYT) ("Amryt" or the "Company"), a...
T The Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa(R) (oral octreotide) in Acromegaly Patients DUBLIN, Ireland, and Boston MA, January...
T Total Voting Rights DUBLIN, Ireland, and Boston MA, January 4, 2022, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and...
T Total Voting Rights DUBLIN, Ireland, and Boston MA, December 1, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and...
T Amryt Pharma plc Director/PDMR Shareholding The following notification is made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the...
T Amryt Provides Update on Regulatory Review Process for Oleogel-S10 FDA PDUFA goal date extended by three months to February 28, 2022 EMA CHMP opinion now expected in January 2022 DUBLIN...
T THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM PURSUANT TO...
The following is a round-up of updates by London-listed companies not separately reported by Alliance News: --------- ...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
